Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage ...

Biliary tract disease describes any disease that affects the biliary tract the gall bladder, bile ducts and accompanying structures. Examples include primary sclerosing cholangitis, secondary ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Biliary tract cancer is a rare adenocarcinoma that occurs in a bile duct, often causing jaundice, pruritus and weight loss. The lesion may be papillary or flat and ulcerated. The tumour is often ...

Biliary tract cancers (BTCs) are rare malignancies arising from the bile ducts. The incidence of BTCs and the associated mortality is rising, risk factors are largely unknown, and early dignosis is ...

Background: The presence of infective microorganisms in the bilio-pancreatic tract is believed to be important in both the onset and outcome of acute biliary pancreatitis. In this study ...

Background: Anti-programmed cell death protein 1 and its ligand (anti-PD1/PDL1) have been proposed as a promising therapeutic option for advanced biliary tract cancer (aBTC). Given the scarce ...

Hepatobiliary cancers, encompassing biliary tract cancer (BTC) and hepatocellular carcinoma (HCC) are highly lethal. Biliary tract cancer is a deadly disease with a very low five-year survival rate.

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...